After 48 months, the combination treatment with VK and ACE-I inhibited the cumulative recurrence of HCC, at least partly through suppression of the vascular endothelial growth factor (VEGF), an angiogenic factor [211]. Here, VEGFA is linked to hepatocellular carcinoma.